WHO ICTRP trial
A comparative clinic study of continuous hepatic artery perfusion combined with…
ChiCTR2100045744 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100045744 |
|---|---|
| Public title | A comparative clinic study of continuous hepatic artery perfusion combined with lenvatinib and lenvatinib alone in the treatment of advanced hepatocellular cancinoma |
| Scientific title | A comparative clinic study of continuous hepatic artery perfusion combined with lenvatinib and lenvatinib alone in the treatment of advanced hepatocellular cancinoma |
| Primary sponsor | Fujian Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2-3 |
| Countries | China |
| Conditions | hepatocellular cancinoma |
| Interventions | Treatment group:Continuous hepatic arterial infusion chemotherapy combined with oral lenvatinib treatment;Control group:Lenvatinib |
| Registration date | Apr 23, 2021 |
| Target size | Treatment group:100;Control group:100 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: